Nebulized Recombinant Tissue Plasminogen Activator (rt-PA) for Acute COVID-19-Induced Respiratory Failure: An Exploratory Proof-of-Concept Trial.
COVID-19 pandemic
acute respiratory illness
critical care
fibrinolytics
inhaled medication
nebulization
recombinant tissue plasminogen activator
targeted therapy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 Sep 2023
08 Sep 2023
Historique:
received:
19
06
2023
revised:
31
08
2023
accepted:
04
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Acute lung injury in COVID-19 results in diffuse alveolar damage with disruption of the alveolar-capillary barrier, coagulation activation, alveolar fibrin deposition and pulmonary capillary thrombi. Nebulized recombinant tissue plasminogen activator (rt-PA) has the potential to facilitate localized thrombolysis in the alveolar compartment and improve oxygenation. In this proof-of-concept safety study, adults with COVID-19-induced respiratory failure and a <300 mmHg PaO
Identifiants
pubmed: 37762789
pii: jcm12185848
doi: 10.3390/jcm12185848
pmc: PMC10531875
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Royal Free Charity
ID : TF 35
Organisme : Boehringer Ingelheim (France)
ID : Drug suppport
Références
QJM. 2020 Aug 1;113(8):539-545
pubmed: 32275753
Thromb Res. 2020 Dec;196:227-230
pubmed: 32916565
Ital J Pediatr. 2014 Feb 13;40(1):18
pubmed: 24524376
Ann Transl Med. 2018 Jan;6(2):36
pubmed: 29430453
Exp Physiol. 2022 Jul;107(7):749-758
pubmed: 35733235
J Cardiovasc Thorac Res. 2015;7(1):28-31
pubmed: 25859313
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Nat Rev Dis Primers. 2019 Mar 14;5(1):18
pubmed: 30872586
Br J Clin Pharmacol. 2003 Dec;56(6):600-12
pubmed: 14616419
Pulm Pharmacol Ther. 2010 Apr;23(2):107-14
pubmed: 19879371
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Crit Care Med. 2003 Apr;31(4 Suppl):S213-20
pubmed: 12682443
Blood. 2020 Mar 5;135(10):724-734
pubmed: 31951652
Front Immunol. 2018 Aug 20;9:1898
pubmed: 30177934
J Inflamm Res. 2021 Dec 21;14:7225-7242
pubmed: 34992415
PLoS One. 2013;8(2):e55262
pubmed: 23408962
Virol J. 2022 May 26;19(1):92
pubmed: 35619180
Thorax. 2002 Jun;57(6):540-6
pubmed: 12037231
Pharm Res. 2005 Oct;22(10):1700-7
pubmed: 16180128
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Anaesth Crit Care Pain Med. 2022 Feb;41(1):101016
pubmed: 34958999
Thorax. 1997 Apr;52 Suppl 2:S31-44
pubmed: 9155849
Am J Respir Crit Care Med. 2015 Dec 1;192(11):1306-13
pubmed: 26192398
Chest. 2022 Mar;161(3):710-727
pubmed: 34592318
Chest. 2016 Aug;150(2):307-13
pubmed: 26836924
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
J Thromb Haemost. 2020 Jul;18(7):1752-1755
pubmed: 32267998
J Thromb Haemost. 2020 Jul;18(7):1548-1555
pubmed: 32329246
Crit Care Med. 2017 Aug;45(8):1317-1324
pubmed: 28538439
N Engl J Med. 1997 Oct 16;337(16):1118-23
pubmed: 9340503
Crit Care Med. 1992 Oct;20(10):1431-40
pubmed: 1395665
Front Med (Lausanne). 2022 May 27;9:829771
pubmed: 35712114
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440